JP2013512250A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013512250A5 JP2013512250A5 JP2012541164A JP2012541164A JP2013512250A5 JP 2013512250 A5 JP2013512250 A5 JP 2013512250A5 JP 2012541164 A JP2012541164 A JP 2012541164A JP 2012541164 A JP2012541164 A JP 2012541164A JP 2013512250 A5 JP2013512250 A5 JP 2013512250A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- pharmaceutical composition
- coating
- taste
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940079593 drug Drugs 0.000 claims 44
- 239000003814 drug Substances 0.000 claims 44
- 239000008194 pharmaceutical composition Substances 0.000 claims 37
- 239000000203 mixture Substances 0.000 claims 34
- 239000011248 coating agent Substances 0.000 claims 30
- 238000000576 coating method Methods 0.000 claims 30
- 239000002245 particle Substances 0.000 claims 23
- 239000010410 layer Substances 0.000 claims 19
- 239000011859 microparticle Substances 0.000 claims 17
- 229920000642 polymer Polymers 0.000 claims 16
- 239000012528 membrane Substances 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 12
- 239000012453 solvate Substances 0.000 claims 12
- 150000002148 esters Chemical class 0.000 claims 11
- 230000000873 masking effect Effects 0.000 claims 11
- 239000006191 orally-disintegrating tablet Substances 0.000 claims 11
- 229920003176 water-insoluble polymer Polymers 0.000 claims 11
- 239000011247 coating layer Substances 0.000 claims 7
- 235000003599 food sweetener Nutrition 0.000 claims 7
- 230000002496 gastric effect Effects 0.000 claims 7
- 239000008187 granular material Substances 0.000 claims 7
- 239000000463 material Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 239000003765 sweetening agent Substances 0.000 claims 7
- 206010013911 Dysgeusia Diseases 0.000 claims 6
- 239000007884 disintegrant Substances 0.000 claims 6
- 230000004584 weight gain Effects 0.000 claims 6
- 235000019786 weight gain Nutrition 0.000 claims 6
- -1 calcium saccharide Chemical class 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 229920001577 copolymer Polymers 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 239000007771 core particle Substances 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 238000001035 drying Methods 0.000 claims 4
- 210000000214 mouth Anatomy 0.000 claims 4
- 230000007935 neutral effect Effects 0.000 claims 4
- 238000004806 packaging method and process Methods 0.000 claims 4
- 239000000725 suspension Substances 0.000 claims 4
- 239000003826 tablet Substances 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 3
- 239000004376 Sucralose Substances 0.000 claims 3
- 150000001720 carbohydrates Chemical class 0.000 claims 3
- 239000003086 colorant Substances 0.000 claims 3
- 238000013270 controlled release Methods 0.000 claims 3
- 238000009826 distribution Methods 0.000 claims 3
- 239000010419 fine particle Substances 0.000 claims 3
- 239000000796 flavoring agent Substances 0.000 claims 3
- 239000012530 fluid Substances 0.000 claims 3
- 235000013355 food flavoring agent Nutrition 0.000 claims 3
- 229920001477 hydrophilic polymer Polymers 0.000 claims 3
- 239000000832 lactitol Substances 0.000 claims 3
- 235000010448 lactitol Nutrition 0.000 claims 3
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims 3
- 229960003451 lactitol Drugs 0.000 claims 3
- 239000000845 maltitol Substances 0.000 claims 3
- 235000010449 maltitol Nutrition 0.000 claims 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims 3
- 229940035436 maltitol Drugs 0.000 claims 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims 3
- 238000002156 mixing Methods 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 239000002861 polymer material Substances 0.000 claims 3
- 239000000565 sealant Substances 0.000 claims 3
- 239000000600 sorbitol Substances 0.000 claims 3
- 229960002920 sorbitol Drugs 0.000 claims 3
- 235000010356 sorbitol Nutrition 0.000 claims 3
- 210000002784 stomach Anatomy 0.000 claims 3
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims 3
- 235000019408 sucralose Nutrition 0.000 claims 3
- 150000005846 sugar alcohols Chemical class 0.000 claims 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical group [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims 2
- 239000001856 Ethyl cellulose Substances 0.000 claims 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 2
- 229920002301 cellulose acetate Polymers 0.000 claims 2
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims 2
- 208000010643 digestive system disease Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000007922 dissolution test Methods 0.000 claims 2
- 229920001249 ethyl cellulose Polymers 0.000 claims 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- 229960003943 hypromellose Drugs 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 238000005461 lubrication Methods 0.000 claims 2
- IWVKTOUOPHGZRX-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.COC(=O)C(C)=C IWVKTOUOPHGZRX-UHFFFAOYSA-N 0.000 claims 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims 2
- 229920002959 polymer blend Polymers 0.000 claims 2
- 229920002689 polyvinyl acetate Polymers 0.000 claims 2
- 239000011118 polyvinyl acetate Substances 0.000 claims 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 230000002441 reversible effect Effects 0.000 claims 2
- 210000003296 saliva Anatomy 0.000 claims 2
- 238000003860 storage Methods 0.000 claims 2
- 238000010998 test method Methods 0.000 claims 2
- IVXUWIUYSLZODX-UHFFFAOYSA-N C(C)N(CC)CC(=O)O.C(C)(=O)OC=C Chemical compound C(C)N(CC)CC(=O)O.C(C)(=O)OC=C IVXUWIUYSLZODX-UHFFFAOYSA-N 0.000 claims 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 1
- 229920003136 Eudragit® L polymer Polymers 0.000 claims 1
- 229920003137 Eudragit® S polymer Polymers 0.000 claims 1
- 229920003134 Eudragit® polymer Polymers 0.000 claims 1
- 239000005955 Ferric phosphate Substances 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 229920001800 Shellac Polymers 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- GUPPESBEIQALOS-UHFFFAOYSA-L calcium tartrate Chemical compound [Ca+2].[O-]C(=O)C(O)C(O)C([O-])=O GUPPESBEIQALOS-UHFFFAOYSA-L 0.000 claims 1
- 239000001427 calcium tartrate Substances 0.000 claims 1
- 235000011035 calcium tartrate Nutrition 0.000 claims 1
- PBUBJNYXWIDFMU-UHFFFAOYSA-L calcium;butanedioate Chemical compound [Ca+2].[O-]C(=O)CCC([O-])=O PBUBJNYXWIDFMU-UHFFFAOYSA-L 0.000 claims 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 239000004148 curcumin Substances 0.000 claims 1
- 239000007919 dispersible tablet Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 238000009506 drug dissolution testing Methods 0.000 claims 1
- 229940088679 drug related substance Drugs 0.000 claims 1
- 229960004887 ferric hydroxide Drugs 0.000 claims 1
- 229940032958 ferric phosphate Drugs 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 229960003284 iron Drugs 0.000 claims 1
- WBJZTOZJJYAKHQ-UHFFFAOYSA-K iron(3+) phosphate Chemical compound [Fe+3].[O-]P([O-])([O-])=O WBJZTOZJJYAKHQ-UHFFFAOYSA-K 0.000 claims 1
- IEECXTSVVFWGSE-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide Chemical compound [OH-].[O-2].[Fe+3] IEECXTSVVFWGSE-UHFFFAOYSA-M 0.000 claims 1
- PVFSDGKDKFSOTB-UHFFFAOYSA-K iron(3+);triacetate Chemical compound [Fe+3].CC([O-])=O.CC([O-])=O.CC([O-])=O PVFSDGKDKFSOTB-UHFFFAOYSA-K 0.000 claims 1
- 229910000399 iron(III) phosphate Inorganic materials 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000001095 magnesium carbonate Substances 0.000 claims 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims 1
- 229960001708 magnesium carbonate Drugs 0.000 claims 1
- 235000014380 magnesium carbonate Nutrition 0.000 claims 1
- 239000004337 magnesium citrate Substances 0.000 claims 1
- 229960005336 magnesium citrate Drugs 0.000 claims 1
- 235000002538 magnesium citrate Nutrition 0.000 claims 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims 1
- 239000000347 magnesium hydroxide Substances 0.000 claims 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims 1
- 229960000816 magnesium hydroxide Drugs 0.000 claims 1
- 235000012254 magnesium hydroxide Nutrition 0.000 claims 1
- 239000004137 magnesium phosphate Substances 0.000 claims 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 claims 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 claims 1
- 229960002261 magnesium phosphate Drugs 0.000 claims 1
- 235000010994 magnesium phosphates Nutrition 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims 1
- 229920006254 polymer film Polymers 0.000 claims 1
- 229920005597 polymer membrane Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 229940069328 povidone Drugs 0.000 claims 1
- 239000011253 protective coating Substances 0.000 claims 1
- 239000004208 shellac Substances 0.000 claims 1
- 229940113147 shellac Drugs 0.000 claims 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims 1
- 235000013874 shellac Nutrition 0.000 claims 1
- 238000005563 spheronization Methods 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 238000012360 testing method Methods 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26521309P | 2009-11-30 | 2009-11-30 | |
| US61/265,213 | 2009-11-30 | ||
| PCT/US2010/057811 WO2011066287A1 (en) | 2009-11-30 | 2010-11-23 | Compressible-coated pharmaceutical compositions and tablets and methods of manufacture |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013512250A JP2013512250A (ja) | 2013-04-11 |
| JP2013512250A5 true JP2013512250A5 (OSRAM) | 2014-01-30 |
| JP5854476B2 JP5854476B2 (ja) | 2016-02-09 |
Family
ID=44066882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012541164A Expired - Fee Related JP5854476B2 (ja) | 2009-11-30 | 2010-11-23 | 圧縮性コーティングで被覆された医薬組成物及び錠剤並びに製造方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20110129530A1 (OSRAM) |
| EP (1) | EP2506835B1 (OSRAM) |
| JP (1) | JP5854476B2 (OSRAM) |
| AR (1) | AR079175A1 (OSRAM) |
| AU (1) | AU2010324835B2 (OSRAM) |
| BR (1) | BR112012012999A2 (OSRAM) |
| CA (1) | CA2782177C (OSRAM) |
| CL (1) | CL2012001404A1 (OSRAM) |
| CO (1) | CO6551722A2 (OSRAM) |
| ES (1) | ES2739888T3 (OSRAM) |
| IL (1) | IL220037A0 (OSRAM) |
| MX (1) | MX337603B (OSRAM) |
| NZ (1) | NZ600123A (OSRAM) |
| RU (1) | RU2012124265A (OSRAM) |
| SG (1) | SG10201407947WA (OSRAM) |
| TW (1) | TWI495491B (OSRAM) |
| UY (1) | UY33062A (OSRAM) |
| WO (1) | WO2011066287A1 (OSRAM) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| EP3403654B1 (en) | 2009-10-01 | 2019-07-31 | Adare Development I, L.P. | Orally administered corticosteroid compositions |
| RU2627471C2 (ru) | 2011-09-14 | 2017-08-08 | Селджин Корпорейшн | Препараты { 2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил} амида циклопропанкарбоновой кислоты |
| EP2844234B1 (de) | 2012-04-27 | 2020-01-08 | Merck Patent GmbH | Tabletten mit überzug und deren herstellung |
| RS59365B1 (sr) * | 2012-06-15 | 2019-11-29 | Pharmathen Sa | Farmaceutska kompozicija koja sadrži polimer koji vezuje fosfat |
| CN104869993B (zh) | 2012-10-25 | 2019-01-15 | 通用医疗公司 | 治疗阿尔茨海默病及相关疾病的组合疗法 |
| US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
| JP6539274B2 (ja) | 2013-08-12 | 2019-07-03 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド | 押出成形された即放性乱用抑止性丸剤 |
| WO2015034678A2 (en) | 2013-09-06 | 2015-03-12 | Aptalis Pharmatech, Inc. | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |
| HK1223541A1 (zh) | 2013-10-22 | 2017-08-04 | The General Hospital Corporation | 色甘酸衍生物以及成像和治疗的相关方法 |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| WO2015120201A1 (en) | 2014-02-05 | 2015-08-13 | Kashiv Pharma, Llc | Abuse-resistant drug formulations with built-in overdose protection |
| WO2015145459A1 (en) * | 2014-03-26 | 2015-10-01 | Sun Pharma Advanced Research Company Ltd. | Abuse deterrent immediate release coated reservoir solid dosage form |
| EP3169315B1 (en) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| ES2774359T3 (es) * | 2014-07-30 | 2020-07-20 | Merck Patent Gmbh | Composición que puede comprimirse directamente que contiene celulosa microcristalina |
| US20160106737A1 (en) | 2014-10-20 | 2016-04-21 | Pharmaceutical Manufacturing Research Services, Inc. | Extended Release Abuse Deterrent Liquid Fill Dosage Form |
| TWI777515B (zh) | 2016-08-18 | 2022-09-11 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
| JP2019524865A (ja) | 2016-08-31 | 2019-09-05 | ザ ジェネラル ホスピタル コーポレイション | 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア |
| KR20190095373A (ko) * | 2016-12-14 | 2019-08-14 | 메르크 파텐트 게엠베하 | 연장된 활성 물질 전달을 갖는 정제를 제조하기 위한 직접 타정성 매트릭스 |
| KR20210070232A (ko) * | 2017-07-20 | 2021-06-14 | 아즈테라피즈 인코포레이티드 | 크로몰린 나트륨 및 이부프로펜의 분말화된 제형 |
| JP2021529771A (ja) | 2018-07-02 | 2021-11-04 | ザ ジェネラル ホスピタル コーポレイション | クロモリンナトリウムおよびα−ラクトースの粉末製剤 |
| US12383528B2 (en) | 2018-12-10 | 2025-08-12 | The General Hospital Corporation | Cromolyn esters and uses thereof |
| GB202001237D0 (en) * | 2020-01-29 | 2020-03-11 | Sisteks D O O | Granular pharmaceutical product for oral administration from a pre-filled straw and method of manufacturing such pharmaceutical product |
| JP7482645B2 (ja) * | 2020-02-18 | 2024-05-14 | 沢井製薬株式会社 | 核粒子を含む顆粒の製造方法 |
| IL297023A (en) | 2020-04-06 | 2022-12-01 | Massachusetts Gen Hospital | Methods for treating inflammatory conditions caused by the corona virus |
| WO2022182869A1 (en) | 2021-02-24 | 2022-09-01 | Bluehalo Llc | System and method for a digitally beamformed phased array feed |
| US12296050B2 (en) | 2023-10-05 | 2025-05-13 | Mirum Pharmaceuticals, Inc. | Pharmaceutical compositions comprising maralixibat and uses thereof |
| WO2025075624A1 (en) * | 2023-10-05 | 2025-04-10 | Mirum Pharmaceuticals, Inc. | Pharmaceutical compositions comprising maralixibat and uses thereof |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5004595A (en) | 1986-12-23 | 1991-04-02 | Warner-Lambert Company | Multiple encapsulated flavor delivery system and method of preparation |
| JP2681601B2 (ja) | 1993-11-01 | 1997-11-26 | 協和醗酵工業株式会社 | 外部滑沢式打錠機 |
| JP2841267B2 (ja) * | 1993-12-17 | 1998-12-24 | エスエス製薬株式会社 | イブプロフェン含有粒剤 |
| JPH09323934A (ja) | 1996-05-31 | 1997-12-16 | Kanebo Ltd | 保存安定性の改善された坐剤 |
| DK0914818T3 (da) | 1996-06-14 | 2005-07-04 | Kyowa Hakko Kogyo Kk | Intraoralt hurtigt desintegrerbar tablet |
| JP4098376B2 (ja) * | 1996-09-05 | 2008-06-11 | ビーエーエスエフ ソシエタス・ヨーロピア | 錠剤特性の優れた水溶性ビタミン組成物およびその製造法 |
| HUP0000116A3 (en) | 1996-10-01 | 2000-08-28 | Stanford Res Inst Int | Taste-masked microcapsule compositions and methods of manufacture |
| CA2327655C (en) | 1998-04-08 | 2010-03-09 | Kyowa Hakko Kogyo Co., Ltd. | Tablet production method and tablet |
| US6740341B1 (en) * | 1998-11-25 | 2004-05-25 | Cima Labs Inc. | Taste masking rapid release coating system |
| US6627223B2 (en) | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
| US6872405B2 (en) * | 2001-05-10 | 2005-03-29 | Yamanouchi Pharmaceutical Co., Ltd. | Quick-disintegrating tablet in buccal cavity and manufacturing method thereof |
| OA12983A (en) * | 2001-07-19 | 2006-10-13 | Pharmacia Corp | Combination of an aldosterone receptor antagonist and an HMG COA reductase inhibitor. |
| US6500454B1 (en) | 2001-10-04 | 2002-12-31 | Eurand Pharmaceuticals Ltd. | Timed, sustained release systems for propranolol |
| US20040185093A1 (en) * | 2003-03-18 | 2004-09-23 | Szymczak Christopher E. | Compositions containing sucralose |
| US7387793B2 (en) | 2003-11-14 | 2008-06-17 | Eurand, Inc. | Modified release dosage forms of skeletal muscle relaxants |
| US8545881B2 (en) | 2004-04-19 | 2013-10-01 | Eurand Pharmaceuticals, Ltd. | Orally disintegrating tablets and methods of manufacture |
| US20060039975A1 (en) * | 2004-08-20 | 2006-02-23 | Zalman Vilkov | Paroxetine formulations |
| US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
| WO2006047493A2 (en) | 2004-10-21 | 2006-05-04 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
| US20060105038A1 (en) | 2004-11-12 | 2006-05-18 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions prepared by coacervation |
| US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
| CN101184478A (zh) * | 2005-05-26 | 2008-05-21 | 卫材R&D管理有限公司 | 口服用组合物的标记方法 |
| WO2007010574A1 (en) | 2005-07-22 | 2007-01-25 | Stmicroelectronics S.R.L. | Integrated pressure sensor with a high full-scale value |
| DE102005051951B4 (de) | 2005-09-23 | 2008-01-10 | Beru Ag | Verfahren zur Reifendruckkontrolle bei mehrachsigen Fahrzeugen |
| AR058605A1 (es) * | 2005-12-22 | 2008-02-13 | Takeda Pharmaceutical | Preparacion solida |
| KR101489401B1 (ko) | 2006-01-27 | 2015-02-03 | 앱탈리스 파마테크, 인코포레이티드 | 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템 |
| CN101410094B (zh) | 2006-01-27 | 2013-04-17 | 阿普塔利斯制药股份有限公司 | 包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统 |
| RU2434630C2 (ru) | 2006-08-31 | 2011-11-27 | Юранд, Инк. | Системы доставки лекарственных средств, включающие в себя твердые растворы слабоосновных лекарственных средств |
| WO2008119033A1 (en) * | 2007-03-27 | 2008-10-02 | Eurand, Inc. | Pharmaceutical compositions comprising an active substance from the substituted benzhydrylpiperazine family |
| WO2009086046A1 (en) * | 2007-12-21 | 2009-07-09 | Eurand, Inc. | Orally disintegrating tablet compositions of temazepam |
| TW200938186A (en) | 2008-02-13 | 2009-09-16 | Eurand Inc | Orally disintegrating tablet compositions of ranitidine and methods of manufacture |
| US8133506B2 (en) | 2008-03-12 | 2012-03-13 | Aptalis Pharmatech, Inc. | Drug delivery systems comprising weakly basic drugs and organic acids |
| TWI519322B (zh) | 2008-04-15 | 2016-02-01 | 愛戴爾製藥股份有限公司 | 包含弱鹼性藥物及控制釋放劑型之組合物 |
| EP2398469A4 (en) | 2009-02-23 | 2013-09-04 | Aptalis Pharmatech Inc | ANTICHOLINERGIC CONTAINING DELAYED RELEASE COMPOSITION |
| US20120128764A1 (en) | 2009-02-23 | 2012-05-24 | Aptalis Pharmatech, Inc. | Controlled-release compositions comprising a proton pump inhibitor |
| RU2554740C2 (ru) * | 2009-05-01 | 2015-06-27 | Апталис Фарматек, Инк. | Композиции перорально распадающихся таблеток, содержащие комбинации высоко- и низкодозовых лекарственных средств |
-
2010
- 2010-11-23 MX MX2012006241A patent/MX337603B/es active IP Right Grant
- 2010-11-23 RU RU2012124265/15A patent/RU2012124265A/ru unknown
- 2010-11-23 NZ NZ600123A patent/NZ600123A/en not_active IP Right Cessation
- 2010-11-23 BR BR112012012999A patent/BR112012012999A2/pt not_active IP Right Cessation
- 2010-11-23 WO PCT/US2010/057811 patent/WO2011066287A1/en not_active Ceased
- 2010-11-23 SG SG10201407947WA patent/SG10201407947WA/en unknown
- 2010-11-23 CA CA2782177A patent/CA2782177C/en not_active Expired - Fee Related
- 2010-11-23 EP EP10833860.9A patent/EP2506835B1/en not_active Not-in-force
- 2010-11-23 JP JP2012541164A patent/JP5854476B2/ja not_active Expired - Fee Related
- 2010-11-23 ES ES10833860T patent/ES2739888T3/es active Active
- 2010-11-23 AU AU2010324835A patent/AU2010324835B2/en not_active Ceased
- 2010-11-25 UY UY0001033062A patent/UY33062A/es not_active Application Discontinuation
- 2010-11-29 TW TW099141291A patent/TWI495491B/zh not_active IP Right Cessation
- 2010-11-30 AR ARP100104427A patent/AR079175A1/es unknown
- 2010-11-30 US US12/956,543 patent/US20110129530A1/en not_active Abandoned
-
2012
- 2012-05-29 IL IL220037A patent/IL220037A0/en unknown
- 2012-05-30 CL CL2012001404A patent/CL2012001404A1/es unknown
- 2012-06-05 CO CO12094058A patent/CO6551722A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013512250A5 (OSRAM) | ||
| US10952971B2 (en) | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers | |
| US11452689B2 (en) | Taste-masked pharmaceutical compositions | |
| JP5845173B2 (ja) | 非オピオイドおよびオピオイド鎮痛薬の組み合わせを含む口腔内崩壊錠組成物 | |
| AU2005307052B2 (en) | Taste-masked multiparticulate pharmaceutical compositions comprising a drug-containing core particle and a solvent-coacervated membrane | |
| RU2012124265A (ru) | Прессуемые покрытые фармацевтические композиции и таблетки, а также способы производства | |
| WO2009102830A1 (en) | Orally disintegrating tablet compositions of ranitidine and methods of manufacture | |
| JP2009524592A (ja) | ランソプラゾール経口崩壊錠剤 | |
| HK1109337B (en) | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers | |
| HK1154515A (en) | Taste-masked multiparticulate pharmaceutical composition comprising a drug-containing core particle and a solvent-coacervated membrane | |
| HK1163502A (en) | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers | |
| HK1107272B (en) | Taste-masked multiparticulate pharmaceutical compositions comprising a drug-containing core particle and a solvent-coacervated membrane |